

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

STA Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
None identified

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
N/a

3. Has any change to the draft scope been agreed to highlight potential equality issues?
No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
N/a

Approved by Associate Director (name): ...Richard Diaz.....

Date: 2/2/2023

Technology appraisals: Scoping

Equality impact assessment for the single technology appraisal of isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658]